Company Analysis

Mesoblast Limited (MESO)

Nasdaq: MESO · Biological Products, (No Diagnostic Substances) · Melbourne, Victoria, AU · filing with the SEC since 2005
Grade5.5
◀ Past 4.5● Present 5.1▶ Future 6.4
2 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in June.

The Form 20-F filed Aug 27, 2026 for the period ended Jun 30, 2026 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.

Income statement, by fiscal year, newest first
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingJun 30, 2026Jun 30, 2025Jun 30, 2024Jun 30, 2023Jun 30, 2022Jun 30, 2021Jun 30, 2020Jun 30, 2019Jun 30, 2018Jun 30, 2017
Report filedAug 27, 2026Aug 29, 2025Aug 29, 2024Aug 31, 2023Aug 31, 2022Aug 31, 2021Sep 3, 2020Sep 9, 2019Aug 31, 2018Aug 30, 2017
Revenue120,25017,1985,9027,50110,211r7,434r32,15616,72217,3412,412
Cost of revenue16,6675,13000······
Research and development97,50934,80739,716r52,816r32,81553,01256,18859,81565,92758,914
Selling, general and administrative57,34639,30924,98027,480······
Finance costs23,83922,96823,00920,12217,28810,71414,109r12,080r1,829·
Interest income····322542719366468
Income before income taxes-56,887-101,812-88,147-82,101-91,586-99,630-87,355-98,754-65,977-90,215
Income tax expense613330-191-212-239-819-9,415-8,955-30,687-13,400
Net income-57,500-102,142-87,956-81,889-91,347-98,811-77,940-89,799-35,290-76,815
Net income to shareholders-57,500-102,142-87,956-81,889-91,347-98,811-77,940-89,799-35,290-76,815
Earnings per share, basic·-0.0846-0.0891-0.1053r-0.1338r-0.1551b-0.14b-0.1725b-0.072b-0.1829b
Earnings per share, diluted·-0.0846-0.0891-0.1053r-0.1338r-0.1551b-0.14b-0.1725b-0.072b-0.1829b
Weighted average shares, basic·1,207,793,132986,702,919777,719,091r682,861,425r636,909,512b556,654,347b520,401,568b490,198,944b420,044,392b
Weighted average shares, diluted·1,207,793,132986,702,919777,719,091r682,861,425r636,909,512b556,654,347b520,401,568b490,198,944b420,044,392b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the change of share basis.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldifrs-full:Revenue
Cost of revenue what it cost to make or buy what it soldifrs-full:CostOfSales
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyifrs-full:SellingGeneralAndAdministrativeExpense
Finance costs what its borrowing costifrs-full:FinanceCosts
Interest income what its cash and investments earnedifrs-full:RevenueFromInterest
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Net income to shareholders the profit or loss that belongs to the company's shareholdersifrs-full:ProfitLossAttributableToOwnersOfParent
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton MESO · research, not advice